Q2 2026 saw 13% organic revenue growth and a 55% increase in adjusted operating income, with adjusted EPS rising to $0.54. FY26 guidance was raised for both organic revenue growth and adjusted EPS, and a major acquisition was announced to strengthen cell therapy capabilities.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.